MTOR and Parkinson disease: Previous studies have demonstrated that inhibition of the mammalian target of rapamycin (mTOR) accelerates autophagy, leading to the reduction of the levels of neurotoxic aggregate proteins such as Tau, α-synuclein, and ataxin [31,32,33], which are associated with diseases such as AD, PD, and spinal ataxia [34,35,36].